Shopping Cart 0
Cart Subtotal
USD 0

Centrexion Therapeutics Corp (CNTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Centrexion Therapeutics Corp (Centrexion Therapeutics), formerly Centrexion Corp is a developer of clinical pipelines of novel and non opioid chronic pain therapy products. The company offers products such as CNTX-4975, CNTX- 0290, CNTX-6970, CNTX-2022, CNTX-6016 and Intrathecalplatform. Its synthetic trans capsaicin ultra-pure injection develops a proprietary injectable therapy designed to provide fast acting, long lasting and targeted pain relief. Centrexion Therapeutics products are used to treat morton's neuroma and knee osteoarthritis. The company's research and clinical trial develops novel pain therapeutics for various conditions. Centrexion Therapeutics is headquartered in Boston, Massachusetts, the US.

Centrexion Therapeutics Corp (CNTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Centrexion Therapeutics Raises USD67 Million in Series D Financing 11

Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 13

Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 14

Centrexion Therapeutics Raises USD11.1 Million in Financing Round 15

Centrexion Therapeutics Raises USD7 Million in Venture Financing 16

Centrexion Raises USD14.7 Million in Venture Financing 17

Centrexion Therapeutics Raises USD8.8 Million in Financing Round 18

Licensing Agreements 19

Centrexion Therapeutics Amends Licensing Agreement with Boehringer Ingelheim 19

Equity Offering 20

Centrexion Therapeutics to Raise up to USD80 Million in IPO of Shares 20

Debt Offering 21

Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21

Centrexion Therapeutics Corp-Key Competitors 22

Centrexion Therapeutics Corp-Key Employees 23

Centrexion Therapeutics Corp-Locations And Subsidiaries 24

Head Office 24

Recent Developments 25

Corporate Communications 25

Sep 24, 2018: Centrexion Therapeutics names Andrew Partridge as executive vice president, chief commercial officer 25

Aug 15, 2018: Centrexion Therapeutics names Dan Mendelson as Board Director 26

Jul 30, 2018: Centrexion Therapeutics names Nick Harvey as chief financial officer 27

Jun 26, 2018: Centrexion Therapeutics Names Joseph R. Swedish As Board Director 28

Jun 26, 2017: Centrexion Therapeutics Names Shawn Tomasello to its Board of Directors 29

Product News 30

08/29/2017: Centrexion Therapeutics to Present 6-Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at PAINWeek 2017 30

06/07/2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology 31

05/10/2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting 32

Product Approvals 33

Jan 16, 2018: Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain 33

Clinical Trials 34

Jan 02, 2018: Centrexion Therapeutics Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018 34

Oct 30, 2017: Centrexion Therapeutics Announces Multiple Data Presentations on CNTX-4975 at the American College of Rheumatology Annual Meeting 2017 35

Sep 26, 2017: Centrexion Therapeutics to Present Phase 2b data of Osteoarthritis Drug Candidate CNTX-4975 at the 11th Annual Pain and Migraine Therapeutics Summit 36

Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton's Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting 37

Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain 38

May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress 40

Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA 41

Mar 16, 2017: Centrexion Therapeutics to Present Late-Breaking Poster at the 33rd Annual American Academy of Pain Medicine Meeting 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Key Facts 2

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Centrexion Therapeutics Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Centrexion Therapeutics Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Centrexion Therapeutics Raises USD67 Million in Series D Financing 11

Centrexion Therapeutics Raises USD5.3 Million in Venture Financing 13

Centrexion Therapeutics Raises USD16.6 Million in Venture Financing 14

Centrexion Therapeutics Raises USD11.1 Million in Financing Round 15

Centrexion Therapeutics Raises USD7 Million in Venture Financing 16

Centrexion Raises USD14.7 Million in Venture Financing 17

Centrexion Therapeutics Raises USD8.8 Million in Financing Round 18

Centrexion Therapeutics Amends Licensing Agreement with Boehringer Ingelheim 19

Centrexion Therapeutics to Raise up to USD80 Million in IPO of Shares 20

Centrexion Therapeutics Raises USD10.5 Million Private Placement of Notes 21

Centrexion Therapeutics Corp, Key Competitors 22

Centrexion Therapeutics Corp, Key Employees 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Centrexion Therapeutics Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.